Paul Tudor Jones's PFE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 181,213 shares of Pfizer Inc. (PFE) worth $4.62 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 1.11 M shares. Largest reduction occurred in Q2 2015, reducing 1.12 M shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +197,701 | Add 0.00% | 197,700 | $28.01 |
| Q3 2013 | +752,300 | Add 380.53% | 950,000 | $28.73 |
| Q4 2013 | -903,753 | Reduce 95.13% | 46,247 | $30.64 |
| Q1 2014 | +828,753 | Add 1792.01% | 875,000 | $32.12 |
| Q2 2014 | -858,800 | Reduce 98.15% | 16,200 | $29.69 |
| Q3 2014 | +89,537 | Add 552.70% | 105,737 | $29.57 |
| Q4 2014 | +279,763 | Add 264.58% | 385,500 | $31.15 |
| Q1 2015 | +753,085 | Add 195.35% | 1.14 M | $34.79 |
| Q2 2015 | -1.12 M | Reduce 98.63% | 15,600 | $33.53 |
| Q3 2015 | +12,700 | Add 81.41% | 28,300 | $31.41 |
| Q4 2015 | +6,600 | Add 23.32% | 34,900 | $32.29 |
| Q1 2016 | -20,300 | Reduce 58.17% | 14,600 | $29.66 |
| Q2 2016 | +6,900 | Add 47.26% | 21,500 | $35.21 |
| Q3 2016 | -4,300 | Reduce 20.00% | 17,200 | $33.90 |
| Q4 2016 | -6,300 | Reduce 36.63% | 10,900 | $32.48 |
| Q1 2017 | -4,500 | Reduce 41.28% | 6,400 | $34.22 |
| Q2 2017 | -6,400 | Sold Out | 6,400 | $0.00 |
| Q4 2017 | +25,136 | New Buy | 25,136 | $36.20 |
| Q1 2018 | -25,136 | Sold Out | 25,136 | $0.00 |
| Q2 2018 | +28,230 | New Buy | 28,230 | $36.27 |
| Q3 2018 | -28,230 | Sold Out | 28,230 | $0.00 |
| Q3 2019 | +15,279 | New Buy | 15,279 | $35.93 |
| Q4 2019 | +142,401 | Add 932.00% | 157,680 | $39.18 |
| Q1 2020 | -157,680 | Sold Out | 157,680 | $0.00 |
| Q2 2020 | +66,810 | New Buy | 66,810 | $32.70 |
| Q3 2020 | +19,393 | Add 29.03% | 86,203 | $36.70 |
| Q4 2020 | -40,892 | Reduce 47.44% | 45,311 | $36.81 |
| Q1 2021 | +2,306 | Add 5.09% | 47,617 | $36.23 |
| Q2 2021 | -25,880 | Reduce 54.35% | 21,737 | $39.15 |
| Q3 2021 | +36,332 | Add 167.14% | 58,069 | $43.02 |
| Q4 2021 | -32,143 | Reduce 55.35% | 25,926 | $59.05 |
| Q1 2022 | +20,243 | Add 78.08% | 46,169 | $51.77 |
| Q2 2022 | -46,169 | Sold Out | 46,169 | $0.00 |
| Q3 2022 | +204,959 | New Buy | 204,959 | $43.76 |
| Q4 2022 | -188,949 | Reduce 92.19% | 16,010 | $0.05 |
| Q1 2023 | +86,799 | Add 542.15% | 102,809 | $0.04 |
| Q2 2023 | +195,437 | Add 190.10% | 298,246 | $36.68 |
| Q3 2023 | -298,246 | Sold Out | 298,246 | $0.00 |
| Q4 2023 | +372,691 | New Buy | 372,691 | $28.79 |
| Q1 2024 | -372,691 | Sold Out | 372,691 | $0.00 |
| Q2 2024 | +209,975 | New Buy | 209,975 | $27.98 |
| Q3 2024 | -166,123 | Reduce 79.12% | 43,852 | $28.94 |
| Q4 2024 | -43,852 | Sold Out | 43,852 | $0.00 |
| Q1 2025 | +1.16 M | New Buy | 1.16 M | $25.34 |
| Q2 2025 | -1.16 M | Sold Out | 1.16 M | $0.00 |
| Q3 2025 | +181,213 | New Buy | 181,213 | $25.48 |
Paul Tudor Jones's Pfizer Investment FAQs
Paul Tudor Jones first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 197,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Pfizer Inc. (PFE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Pfizer Inc. (PFE) was in Q1 2025, adding 1,156,325 shares worth $29.3 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 181,213 shares of Pfizer Inc. (PFE), valued at approximately $4.62 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Pfizer Inc. (PFE) was 1,156,325 shares, as reported at the end of Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.